Munich, 9 March 2020 – The science and technology company Merck has signed a Cooperation Agreement with 3D printing specialist AMCM (Starnberg). The companies intend to jointly develop 3D-printed tablets and are currently working on developing a GMP-conform (Good Manufacturing Practice) tablet formulation and the production for clinical trials. Later, full digital solutions at commercial scale will follow.
A team, acting across offices and led by Beiten Burkhardt partners Dr Holger Weimann and Dr Andreas Lober, provided comprehensive legal advice to Merck on the Cooperation Agreement, which represents a giant step towards digitalisation for the market.
In the Innovation Center at Merck headquarters in Darmstadt project teams work on developing and upscaling ideas to create new businesses between and beyond the three Merck business sectors Healthcare, Life Science and Performance Materials. The partnership with AMCM, a sister company of EOS, the world market leader in 3D printing, especially laser sintering applying the powder bed method, will allow for a massive move towards digitalisation of the industry, establishing the next generation of tablet production through 3D printing. As a result tablet manufacturing can become faster and cheaper.
The vision is to allow a flexible and sustainable local tablet production according to specific market requirements as well as adaptation to patient Needs.
BEITEN BURKHARDT: Partners Dr Holger Weimann (IT/IP, Munich), Dr Andreas Lober (IT/IP, Frankfurt am Main, both in charge), Katharina Mayerbacher (IT/IP, Munich), Wojtek Ropel (IT/IP, Frankfurt am Main), Christoph Heinrich (Antitrust law, Munich).
MERCK KGaA: Dr Christoph Hüls (Project Lead/Intrapreneur), Dr Marco Rau (Head of Legal Team Strategy & Transformation, Group Legal Services), Stefan Greening (Commercial/IT, Legal Team Strategy & Transformation, Group Legal Services).
Contact
Phone: +49 89 3 50 65 – 1312
E-mail: Holger.Weimann@bblaw.com
